Comparison of Biologics and Janus Kinase inhibitor agents in the treatment of Rheumatoid Arthritis using Routine Assessment of Patient Index Data 3 Score Trends (TIJITRA)

Abstract

Specific Aims: To identify which class of agents used for the treatment of rheumatoid arthritis had the best outcomes when it comes to disease response at Banner Family Specialty Pharmacy. Outcomes to the biologic agents (Humira, and Enbrel) will be compared to JAK inhibitors, the newer class of DMARDs agents, (Xeljanz and Rinvoq) using RAPID3 scores. To determine if demographic variables such as age, or gender, influence RAPID3 scores for each agent. Methods: This study is a retrospective cohort study looking at RAPID3 scores from patients being treated by Banner Family Pharmacy. Patients will be included in the study only if the baseline RAPID3 score (new to therapy) was retrieved between 2018 and July 2020 and had at least 2 follow ups by clinical pharmacists. Patients will be excluded if patients did not complete the baseline RAPID3 within 0-3 weeks of starting therapy. Main Results: A total of 48 patients met inclusion criteria and were assigned to a study group. A total of 8 men (mean age = 54; SD = 7.17) and 35 women (mean age = 50.31; SD = 14.07) were assigned to the Humira/Enbrel group and 5 women (mean age = 56; SD = 8.72) were assigned to the Rinvoq/Xeljanz group. Overall, RAPID3 scores were not significantly different from baseline for both groups F=1.58 (p=0.21) for the Humira/Enbrel group and F=1.39 (p=0.30) for the Rinvoq/Xeljanz group. Conclusions: Follow up RAPID3 scores in patients who received Humira/Enbrel or Rinvoq/Xeljanz were similar to baseline.